Correlation Between Pmv Pharmaceuticals and Inhibikase Therapeutics
Can any of the company-specific risk be diversified away by investing in both Pmv Pharmaceuticals and Inhibikase Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pmv Pharmaceuticals and Inhibikase Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Pmv Pharmaceuticals and Inhibikase Therapeutics, you can compare the effects of market volatilities on Pmv Pharmaceuticals and Inhibikase Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pmv Pharmaceuticals with a short position of Inhibikase Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pmv Pharmaceuticals and Inhibikase Therapeutics.
Diversification Opportunities for Pmv Pharmaceuticals and Inhibikase Therapeutics
0.87 | Correlation Coefficient |
Very poor diversification
The 3 months correlation between Pmv and Inhibikase is 0.87. Overlapping area represents the amount of risk that can be diversified away by holding Pmv Pharmaceuticals and Inhibikase Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibikase Therapeutics and Pmv Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pmv Pharmaceuticals are associated (or correlated) with Inhibikase Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibikase Therapeutics has no effect on the direction of Pmv Pharmaceuticals i.e., Pmv Pharmaceuticals and Inhibikase Therapeutics go up and down completely randomly.
Pair Corralation between Pmv Pharmaceuticals and Inhibikase Therapeutics
Given the investment horizon of 90 days Pmv Pharmaceuticals is expected to under-perform the Inhibikase Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Pmv Pharmaceuticals is 2.34 times less risky than Inhibikase Therapeutics. The stock trades about 0.0 of its potential returns per unit of risk. The Inhibikase Therapeutics is currently generating about 0.09 of returns per unit of risk over similar time horizon. If you would invest 182.00 in Inhibikase Therapeutics on September 2, 2024 and sell it today you would earn a total of 110.00 from holding Inhibikase Therapeutics or generate 60.44% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Strong |
| Accuracy | 100.0% |
| Values | Daily Returns |
Pmv Pharmaceuticals vs. Inhibikase Therapeutics
Performance |
| Timeline |
| Pmv Pharmaceuticals |
| Inhibikase Therapeutics |
Pmv Pharmaceuticals and Inhibikase Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Pmv Pharmaceuticals and Inhibikase Therapeutics
The main advantage of trading using opposite Pmv Pharmaceuticals and Inhibikase Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pmv Pharmaceuticals position performs unexpectedly, Inhibikase Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibikase Therapeutics will offset losses from the drop in Inhibikase Therapeutics' long position.| Pmv Pharmaceuticals vs. Eliem Therapeutics | Pmv Pharmaceuticals vs. MediciNova | Pmv Pharmaceuticals vs. Pharvaris BV | Pmv Pharmaceuticals vs. PepGen |
| Inhibikase Therapeutics vs. DiaMedica Therapeutics | Inhibikase Therapeutics vs. Milestone Pharmaceuticals | Inhibikase Therapeutics vs. Seres Therapeutics | Inhibikase Therapeutics vs. Oncolytics Biotech |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Complementary Tools
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |